Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
Cells. 2023 Jan 19;12(3):365. doi: 10.3390/cells12030365.
Immunotherapy has brought new hope for cancer patients in recent times. However, despite the promising success of immunotherapy, there is still a need to address major challenges including heterogeneity in response among patients, the reoccurrence of the disease, and iRAEs (immune-related adverse effects). The first critical step towards solving these issues is understanding the epigenomic events that play a significant role in the regulation of specific biomolecules in the context of the immune population present in the tumor immune microenvironment (TIME) during various treatments and responses. A prominent advantage of this step is that it would enable researchers to harness the reversibility of epigenetic modifications for their druggability. Therefore, we reviewed the crucial studies in which varying epigenomic events were captured with immuno-oncology set-ups. Finally, we discuss the therapeutic possibilities of their utilization for the betterment of immunotherapy in terms of diagnosis, progression, and cure for cancer patients.
免疫疗法最近为癌症患者带来了新的希望。然而,尽管免疫疗法取得了有希望的成功,但仍需要解决包括患者反应异质性、疾病复发和 iRAEs(免疫相关不良反应)在内的重大挑战。解决这些问题的关键第一步是了解在肿瘤免疫微环境 (TIME) 中存在的免疫群体中,各种治疗和反应过程中,对特定生物分子起调节作用的表观基因组事件。这一步的一个显著优势是,它将使研究人员能够利用表观遗传修饰的可逆性使其具有成药性。因此,我们回顾了使用免疫肿瘤学方法捕获不同表观基因组事件的重要研究。最后,我们讨论了它们在改善癌症患者的免疫治疗方面的诊断、进展和治愈方面的治疗可能性。